5-甲基-4,5,6,7-四氢[1,3]噻唑并[5,4-C]吡啶-2-胺 | 17899-48-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 5-甲基-4,5,6,7-四氢[1,3]噻唑并[5,4-C]吡啶-2-胺
• 英文名称: 2-amino-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine
• 英文别名: 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-amine；5-Methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-amine；5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-amine
• CAS: 17899-48-8
• 化学式: C₇H₁₁N₃S
• mdl: MFCD02854749
• 分子量: 169.25
• InChiKey: SAFPFEWXCCYGOX-UHFFFAOYSA-N

物化性质

• 沸点：
  315.5±32.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  70.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-amine
CAS number: 17899-48-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H11N3S
Molecular weight: 169.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基-4,5,6,7-四氢[1,3]噻唑并[5,4-C]吡啶-2-胺 在 阻聚剂701 、 甲烷磺酸 、 氢溴酸 、 sodium hydroxide 、 sodium nitrite 作用下， 以 乙醇 、 二氯甲烷 、 水 、 异丙醇 、 乙腈 为溶剂， 反应 21.0h， 生成 伊多塞班对甲苯磺酸盐
  参考文献：
  名称：

  PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST

  摘要：

  本发明提供了一种新型方法，通过使用一种新型的桑迷尔反应，利用一种亚硝基自由基化合物作为反应催化剂，从芳香氨基化合物的芳香重氮盐进行转化反应，以稳定高产率制备取代芳香化合物，如芳香卤素化合物或其盐。

  公开号：

  US20130144061A1
• 作为产物：
  描述：

  N-甲基-4-哌啶酮 、 氰胺 在 四氢吡咯 、 sulfur 作用下， 以 异丙醇 为溶剂， 以59%的产率得到5-甲基-4,5,6,7-四氢[1,3]噻唑并[5,4-C]吡啶-2-胺
  参考文献：
  名称：

  8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS

  摘要：

  提供了公式II的8-氟邻菲啉-1(2H)-酮化合物，其中X1、X2和X3中的一个或两个是N，包括立体异构体、互变异构体和其药用可接受盐，用于抑制Btk激酶，并用于治疗由Btk激酶介导的炎症等免疫紊乱。公开了使用公式II化合物进行哺乳动物细胞中的体外、体内和体内诊断以及治疗这类疾病或相关病理条件的方法。

  公开号：

  US20130116246A1

文献信息

• [EN] BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS BIARYLAMIDE DE PRODUCTION DE LEUKOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012082817A1

  公开（公告）日：2012-06-21

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, R1a, R1b, R2, R3, R4a and R4b are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物及其药学上可接受的盐，其中A、B、C、R1a、R1b、R2、R3、R4a和R4b如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• METHOD FOR PRODUCING INHIBITOR OF ACTIVATED BLOOD COAGULATION FACTOR X (FXA)
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20170050983A1

  公开（公告）日：2017-02-23

  An object of the present invention is to provide a novel method for producing a compound, a salt thereof, or a hydrate of the compound or the salt, which is an FXa inhibitor. The object can be attained by a production method in which a production method via a compound represented by formula (1-1), etc., from a compound represented by the following formula (1-x), etc., is used for a method for producing a compound represented by the following formula (X), etc. [wherein X represents a halogen atom or the like, and R 1 represents an optionally substituted phenyl group].

  本发明的目的是提供一种新型的化合物、其盐或其水合物的生产方法，该化合物是一种FXa抑制剂。可以通过使用以下公式（1-x）等所代表的化合物，经过公式（1-1）等所代表的化合物生产方法来达到这个目标，用于生产以下公式（X）等所代表的化合物的方法[其中X代表卤素原子等，R1代表可选地被取代的苯基团]。
• [EN] RHO KINASE INHIBITORS<br/>[FR] INHIBITEURS DES RHO-KINASES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012054367A1

  公开（公告）日：2012-04-26

  The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及公式I的化合物及其药用盐，其中R1、R2、R3和X如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PHARMACYCLICS LLC

  公开号：WO2016004272A1

  公开（公告）日：2016-01-07

  Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了抑制布鲁顿酪氨酸激酶（Btk）的化合物。还描述了Btk的不可逆抑制剂。此外，还描述了Btk的可逆抑制剂。还披露了包括这些化合物的药物组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症（包括淋巴瘤）和炎症性疾病或症状。
• 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
  申请人：MSD Oss B.V.

  公开号：EP2548877A1

  公开（公告）日：2013-01-23

  The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

  本发明提供了根据式I提供的6-5成员融合吡啶环化合物或其药学上可接受的盐。 或其药学上可接受的盐，或包含这些化合物的药物组合物以及它们在治疗中的使用。具体而言，本发明涉及在治疗布鲁顿氏酪氨酸激酶（Btk）介导的疾病中使用6-5成员融合吡啶环化合物。